The “liquid biopsy” tests can identify tiny amounts of genetic material in a patient’s blood to provide physicians insight as to what types of treatment may be most effective for the individual, according to the report. Blood tests for cancer detection are commonly used for patients with stage 3 or 4 cancer.
“We’re not that far away from seeing the promise becoming a reality of a blood test for early detection,” Guardant Health Co-founder and CEO Helmy Eltoukhy told CNBC.
In 2018, Guardant Health’s blood tests were used in 50 types of cancers. The company anticipates liquid biopsies will assist patients when tissue biopsies cannot, such as when the tissue would be too difficult to obtain, according to the report.
More articles on health IT:
Dell Medical School explores blockchain use in healthcare
Why do employees create hackable passwords? It’s personal, not laziness
Threats, vulnerabilities of medical device cyberattacks: 4 Qs with UC Davis cybersecurity expert Dr. Jeff Tully
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
